Lungpacer Medical filed an SEC Form D earlier this week to confirm the sale of nearly $16 million in an equity financing. Vancouver, Canada-based Lungpacer develops a diaphragm pacing therapy system (DPTS) to assist in weaning patients off mechanical ventilation who are determined by a healthcare provider to be at high risk of weaning failure. […]
Lungpacer Medical
FDA grants EUA to Lungpacer for diaphragm pacing system
Lungpacer Medical announced last week that it received FDA emergency use authorization (EUA) for use of its diaphragm pacing therapy system (DPTS) in some COVID-19 cases. The Vancouver, Canada–based company designed its DPTS to assist in weaning patients who are determined by a healthcare provider to be at high risk of weaning failure. In a […]
Lungpacer Medical hits the FDA fast track with phrenic nerve pacer
Lungpacer Medical said it won an expedited access pathway designation from the FDA for the diaphragm pacing system it’s developing to treat patients who can’t be weaned from mechanical ventilation. The Lungpacer DPS device is a neurostimulation system designed to exercise and strengthen the diaphragm via the temporary, transcatheter stimulation of the phrenic nerve. The FDA’s […]
